A Phase 1 and Pharmacologic Study of MM-151 in Patients with Refractory Advanced Solid Tumors
Description: 

The main purpose of this study is to find the dose of MM-151 that does not cause unacceptable side effects ('maximum tolerated dose') or the doseof MM-151 that produces the best drug concentration level in the human body (recommended dose). Researchers are also trying to learn about: The side effects of MM-151, How MM-151 is broken down in the human body, how safe and tolerable MM-151 is for patients.

Study Number: 

I 204511

Phase: 
I
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT01520389

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.